Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BRAIN Biotech AG is a leading European technology company specializing in industrial biotechnology. Founded in 1993 and headquartered in Zwingenberg, Germany, it develops and commercializes bio-based products and solutions, including bioactive natural compounds, proprietary enzymes, high-performance microorganisms, and microbial production strains. The company supports the biologization of industries in nutrition, health, environment, pharmaceuticals, food, feed, chemicals, and life sciences, contributing to sustainability by addressing UN Sustainable Development Goals such as zero hunger, good health, clean water, industry innovation, and responsible consumption. Its business operates through two key pillars: BioScience, encompassing contract research and an incubator for innovative products with significant economic and environmental impact; and BioIndustrial, focusing on the production, refinement, and distribution of specialty enzymes, microorganisms, and natural products. BRAIN Biotech AG maintains the BRAIN Bioarchive, a diverse collection of microorganisms, genetic material, and natural substances, complemented by production facilities in Continental Europe, the UK, and the US. With over 30 years of expertise, it provides end-to-end services from discovery and optimization to large-scale manufacturing, enabling more efficient and sustainable industrial processes.
The business is unprofitable at the operating level (-14.89% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 8.4% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -26.62% to -31.75%, capital efficiency is deteriorating. Negative free cash flow of -€11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€48M
▼ -8.4% YoY
Net Income (TTM)
-€11M
▼ -6.6% YoY
Op. Margin
-14.03%
▲ +1.9pp YoY
ROIC
-31.75%
▼ -5.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€8M
▼ -104.0% YoY
Op. Cash Flow (TTM)
-€8M
▼ -171.0% YoY
Net Debt
€2M
Cash & Equiv.
€6M
3Y CAGR: +0.3%
Continue Research